Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Oncology·MeSH: Leukemia, Lymphocytic, Chronic, B-Cell
Prevalence
20.0 / 100K
Incidence
4.7 / 100K/yr
2 drugs in development·2 companies·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Sonrotoclax | ENANTA PHARMACEUTICALS INC (ENTA) |
Phase 2(1)
| Drug | Company |
|---|---|
| dzd8586 | NYMOX PHARMACEUTICAL CORP (NYMXF) |
Compare drugs
Frequently asked questions
How many drugs are in development for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma?
BioSniper tracks 2 drugs in development for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma across 2 companies.
How many clinical trials target Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma?
There are 2 clinical trials targeting Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma tracked by BioSniper.
What is the prevalence of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma?
The estimated prevalence of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma is approximately 20.0 per 100,000 population.
Deep-dive into Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis